Fondaparinux free base | CAS# 104993-28-4 (free base) | synthetic pentasaccharide

MedKoo Cat#: 414613 | Name: Fondaparinux free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fondaparinux Free Base is a synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery. Fondaparinux is a clinically approved anticoagulant pentasaccharide for the treatment of thrombotic diseases, displays better efficacy and biosafety than other heparin-based anticoagulant drugs.

Chemical Structure

Fondaparinux free base

CAS#104993-28-4 (free base)

Theoretical Analysis

MedKoo Cat#: 414613

Name: Fondaparinux free base

CAS#: 104993-28-4 (free base)

Chemical Formula: C31H53N3O49S8

Exact Mass: 1506.9513

Molecular Weight: 1508.22

Elemental Analysis: C, 24.69; H, 3.54; N, 2.79; O, 51.98; S, 17.01

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

104993-28-4 (free base) 114870-03-0 (sodium)

Synonym

Fondaparinux Free Base; Natural heparin pentasaccharide; Arixtra; Fondaparin; Org-31540; Org31540; Org 31540; SR-90107; SR90107; SR 90107

IUPAC/Chemical Name

(2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-carboxy-4-hydroxy-6-(((2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfooxy)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfoamino)-4-(sulfooxy)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-3-(((2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfoamino)-6-((sulfooxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4,5-dihydroxytetrahydro-2H-pyran-2-carboxylic acid

InChi Key

KANJSNBRCNMZMV-ABRZTLGGSA-N

InChi Code

InChI=1S/C31H53N3O49S8/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68)/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-/m1/s1

SMILES Code

CO[C@H]1O[C@@H]([C@H]([C@@H]([C@H]1NS(=O)(O)=O)O)O[C@@H]2O[C@@H](C(O)=O)[C@H]([C@@H]([C@H]2OS(=O)(O)=O)O)O[C@H]3O[C@@H]([C@H]([C@@H]([C@H]3NS(=O)(O)=O)OS(=O)(O)=O)O[C@@H]4O[C@H](C(O)=O)[C@H]([C@@H]([C@H]4O)O)O[C@H]5O[C@@H]([C@H]([C@@H]([C@H]5NS(=O)(O)=O)O)O)COS(=O)(O)=O)COS(=O)(O)=O)COS(=O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,508.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Bauersachs RM. Fondaparinux Sodium: Recent Advances in the Management of Thrombosis. J Cardiovasc Pharmacol Ther. 2023 Jan-Dec;28:10742484221145010. doi: 10.1177/10742484221145010. PMID: 36594404. 2: Zhang L, Liu Y, Xu Z, Hao T, Wang PG, Zhao W, Li T. Design and Synthesis of Neutralizable Fondaparinux. JACS Au. 2022 Nov 14;2(12):2791-2799. doi: 10.1021/jacsau.2c00537. PMID: 36590263; PMCID: PMC9795572. 3: Thein KZ, Elsaim SA, Ma MQ, Rojas Hernandez CM, Elsayem A. Heparin-Induced Thrombocytopenia at the Emergency Department Due to Intermittent Heparin Flush in a Patient Undergoing Stem Cell Transplant. Cureus. 2022 Nov 22;14(11):e31798. doi: 10.7759/cureus.31798. PMID: 36569714; PMCID: PMC9780017. 4: Abrignani MG, Lombardo A, Braschi A, Renda N, Abrignani V, Lombardo RM. Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation. World J Cardiol. 2022 Nov 26;14(11):576-598. doi: 10.4330/wjc.v14.i11.576. PMID: 36483763; PMCID: PMC9724000. 5: Zhao KN, Masci P, Dimeski G, Johnson L, Grant M, de Jersey J, Lavin MF. Potential Application of Recombinant Snake Prothrombin Activator Ecarin in Blood Diagnostics. Biomolecules. 2022 Nov 17;12(11):1704. doi: 10.3390/biom12111704. PMID: 36421717; PMCID: PMC9687618. 6: Ertan-Bolelli T, Bolelli K, Elçi SD, Belen-Apak FB. Promising Drug Fondaparinux for the Treatment of COVID-19: an In Silico Analysis of Low Molecular Weight Heparin, Direct Oral Anticoagulant, and Antiplatelet Drug Interactions with Host Protease Furin. Cardiovasc Drugs Ther. 2022 Nov 19:1–8. doi: 10.1007/s10557-022-07406-z. Epub ahead of print. PMID: 36401727; PMCID: PMC9676724. 7: Boytsov SA, Shakhnovich RM, Tereschenko SN, Erlikh AD, Pevsner DV, Gulyan RG. Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM. Kardiologiia. 2022 Oct 30;62(10):3-15. Russian, English. doi: 10.18087/cardio.2022.10.n2238. PMID: 36384404. 8: Langer F, Gerlach HE, Schimke A, Heinken A, Hoffmann U, Noppeney T, Pittrow D, Klotsche J, Rabe E, Bauersachs R; INSIGHTS-SVT study group. Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice. Thromb Res. 2022 Dec;220:145-152. doi: 10.1016/j.thromres.2022.10.022. Epub 2022 Nov 5. PMID: 36370650. 9: Apostu D, Berechet B, Oltean-Dan D, Mester A, Petrushev B, Popa C, Gherman ML, Tigu AB, Tomuleasa CI, Barbu-Tudoran L, Benea HRC, Piciu D. Low-Molecular- Weight Heparins (LMWH) and Synthetic Factor X Inhibitors Can Impair the Osseointegration Process of a Titanium Implant in an Interventional Animal Study. Medicina (Kaunas). 2022 Nov 3;58(11):1590. doi: 10.3390/medicina58111590. PMID: 36363548; PMCID: PMC9694659. 10: Murray A, Yan L, Gibson JM, Liu J, Eliezer D, Lippens G, Zhang F, Linhardt RJ, Zhao J, Wang C. Proline-Rich Region II (PRR2) Plays an Important Role in Tau-Glycan Interaction: An NMR Study. Biomolecules. 2022 Oct 27;12(11):1573. doi: 10.3390/biom12111573. PMID: 36358923; PMCID: PMC9687896. 11: Yamashita A, Hisatake S, Kiuchi S, Kabuki T, Ikeda T. Effectiveness of Fondaparinux in the Japanese Population with Acute Venous Thromboembolism -A Study Comparing Patients with and without Cancer. Intern Med. 2022 Nov 2. doi: 10.2169/internalmedicine.0296-22. Epub ahead of print. PMID: 36328572. 12: Abo Elmaaty A, Eldehna WM, Khattab M, Kutkat O, Alnajjar R, El-Taweel AN, Al-Rashood ST, Abourehab MAS, Binjubair FA, Saleh MA, Belal A, Al-Karmalawy AA. Anticoagulants as Potential SARS-CoV-2 Mpro Inhibitors for COVID-19 Patients: In Vitro, Molecular Docking, Molecular Dynamics, DFT, and SAR Studies. Int J Mol Sci. 2022 Oct 13;23(20):12235. doi: 10.3390/ijms232012235. PMID: 36293094; PMCID: PMC9603561. 13: Nusanti S, Putera I, Sidik M, Edwar L, Koesnoe S, Rachman A, Kurniawan M, Edi Tarigan TJ, Yunus RE, Saraswati I, Zoraida Soraya SH, Pratomo TG, Nora RD. A case of aseptic bilateral cavernous sinus thrombosis following a recent inactivated SARS-CoV-2 vaccination. Taiwan J Ophthalmol. 2022 Jun 15;12(3):334-338. doi: 10.4103/tjo.tjo_25_22. PMID: 36248079; PMCID: PMC9558469. 14: Zhang G, Yang K, Wang L, Cheng Y, Liu C. Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin. Org Biomol Chem. 2022 Nov 2;20(42):8323-8330. doi: 10.1039/d2ob01221a. PMID: 36239281. 15: Muhamad N, Abu MA, Kalok AH, Shafiee MN, Shah SA, Ismail NAM. Safety and effectiveness of fondaparinux as a postpartum thromboprophylaxis during puerperium among muslim women: A single centre prospective study. Front Pharmacol. 2022 Sep 23;13:887020. doi: 10.3389/fphar.2022.887020. PMID: 36210844; PMCID: PMC9540499. 16: Santagata D, Cammà G, Donadini MP, Squizzato A, Ageno W. Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients. Expert Opin Pharmacother. 2022 Oct;23(14):1651-1665. doi: 10.1080/14656566.2022.2128757. Epub 2022 Oct 3. PMID: 36154548. 17: Sayar Z, Burke S, Mittal P, Cohen H. The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome. Lupus. 2022 Oct;31(12):1485-1490. doi: 10.1177/09612033221122147. Epub 2022 Sep 8. PMID: 36074077; PMCID: PMC9580031. 18: Wettstein L, Immenschuh P, Weil T, Conzelmann C, Almeida-Hernández Y, Hoffmann M, Kempf A, Nehlmeier I, Lotke R, Petersen M, Stenger S, Kirchhoff F, Sauter D, Pöhlmann S, Sanchez-Garcia E, Münch J. Native and activated antithrombin inhibits TMPRSS2 activity and SARS-CoV-2 infection. J Med Virol. 2023 Jan;95(1):e28124. doi: 10.1002/jmv.28124. Epub 2022 Sep 16. PMID: 36056630; PMCID: PMC9538173. 19: Soto Alsar J, Gutiérrez Ortiz de la Tabla A, Ortega Morán L, Muñoz Martín AJ. Treatment modalities in cancer-associated venous thromboembolism (VTE). Best Pract Res Clin Haematol. 2022 Mar;35(1):101354. doi: 10.1016/j.beha.2022.101354. Epub 2022 Jun 20. PMID: 36030074. 20: Russo V, Caputo A, Imbalzano E, Di Micco P, Frontera A, Uccello A, Orlando L, Galimberti P, Golino P, D'Andrea A. The pharmacology of anticoagulant drug treatment options in COVID-19 patients: reviewing real-world evidence in clinical practice. Expert Rev Clin Pharmacol. 2022 Sep;15(9):1095-1105. doi: 10.1080/17512433.2022.2117154. Epub 2022 Sep 6. PMID: 36017645.